Phase 2 RCT of 69 adults with mild to moderate hidradenitis suppurativa: 1.5% ruxolitinib cream vs vehicle reduced abscess and inflammatory nodule count at week 16 (LS mean -3.61 vs -2.42; P = .0215), with fewer flares and no grade ≥3 adverse events.
RCTn = 69
Porter et al. Efficacy and safety of ruxolitinib cream in patients with mild to moderate hidradenitis suppurativa: Results from a randomized, double-blind, vehicle-controlled phase 2 study